Replies to post #55196 on Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

What is your view, if there is approval, on the issue of market acceptance by the EU medical community, due to the limitations of the data that ADXS is using?

I hear a conversation from clinical experts, including one European, that the Advaxis approach is a challenge and has been from beginning to end. The addendum?

"But it's cervical cancer."

And I personally think that says it all. Docs everywhere recognize the critical unmet need here, and if there is a new approved therapy, I think they'll clamor to at least TRY it. That does not guarantee approval or post-marketing success, but the outlook is pretty grim at this time, as you know.

Of course, it's good that there is finally movement by ADXS here, since other immunotherapies might be coming along to challenge their potential market position. How would docs theoretically select among different agents? That's where strength of data will be important.